Abstract
When kidney function is compromised, myriad metabolites and peptides - uraemic retention molecules (URMs) - accumulate in the body and compromise homeostasis. Over 150 molecules have been classified as URMs but omics approaches are revealing many more. When URMs exert pathophysiological effects and/or are associated with relevant adverse patient outcomes, they are called uraemic toxins. The origins of uraemic toxins and their contributions to post-translational modification of proteins are important current areas of research. Although most research has thus far focused on uraemic toxins, new studies have also identified URMs with the potential to counteract harmful biological changes that might thus confer a beneficial effect. To tackle the growing burden of chronic kidney disease, preventive therapeutic measures must target the disease early in its course and a balanced view of uraemic retention is needed to understand the role of URMs in kidney disease progression. Knowledge of the origin of the solutes, their kinetics, context-dependent biological profile and the involvement of transporter-mediated interorgan communication by small molecules - termed 'remote sensing and signalling' - is indispensable to facilitate the development of interventions that can promote or restore homeostasis in people with kidney dysfunction.
| Original language | English |
|---|---|
| Pages (from-to) | 50-68 |
| Number of pages | 19 |
| Journal | Nature Reviews. Nephrology |
| Volume | 22 |
| Issue number | 1 |
| Early online date | 23 Sept 2025 |
| DOIs | |
| Publication status | Published - Jan 2026 |
Bibliographical note
Publisher Copyright:© Springer Nature Limited 2025.
Funding
The authors thank the members of the EUTox work group for their ideas, research, discussions and efforts in standardizing uraemic toxin-related research: A. Argiles, Montpellier, France; J. Beige, Leipzig, Germany; P. Brunet, Marseille, France; J.-M. Chillon, Amiens, France; G. Cohen, Vienna, Austria; O. Abou Deif, Hamburg, Germany; D. Fliser, Homburg/Saar, Germany; I. Fridolin, Tallinn, Estonia; V. Jankowski, Aachen, Germany; Z. A. Massy, Paris, France; H. Mischak, Hannover, Germany; A. Ortiz, Madrid, Spain; A. Perna, Naples, Italy; J. Mariano Rodriguez-Portillo, Cordoba, Spain; J. Schanstra, Toulouse, France; J. Siwy, Hannover, Germany; G. Spasovski, Skopje, Republic of North Macedonia; D. Stamatialis, Twente, The Netherlands; B. G. Stegmayr, Umea, Sweden; P. Stenvinkel, Stockholm, Sweden; R. Stojanov, Skopje, Republic of North Macedonia; A. Vlahou, Athens, Greece; and A. Wiecek, Katowice, Poland. All authors are members of the EUTox work group. J.J. is supported by grants from the Interdisciplinary Center for Clinical Research within the Faculty of Medicine at the RWTH Aachen University and the ‘Deutsche Forschungsgemeinschaft‘ (DFG, German Research Foundation) by the Transregional Collaborative Research Centre (Project-ID 322900939), INST 948/4S-1, CRU 5011 (Project-ID 445703531) and IZKF FACROSS and Phase Transition in Disease (1-1) of the University of Aachen (Germany) Cost-Action CA 21165, ERA-PerMed (ERA-PERMED2022-202-KidneySign).
| Funders | Funder number |
|---|---|
| IZKF FACROSS | |
| RWTH Aachen University | |
| Deutsche Forschungsgemeinschaft | |
| Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg | |
| Transregional Collaborative Research Centre | 322900939, 445703531 |
| University of Aachen | CA 21165, ERA-PERMED2022-202-KidneySign |